- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
Patent holdings for IPC class A61K 31/535
Total number of patents in this class: 1131
10-year publication summary
|
63
|
49
|
34
|
41
|
21
|
22
|
23
|
18
|
24
|
10
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Glaxosmithkline LLC | 526 |
29 |
| Merck Sharp & Dohme Corp. | 2183 |
22 |
| Merck Sharp & Dohme LLC | 3736 |
22 |
| Novartis AG | 10178 |
20 |
| Bristol-myers Squibb Company | 4748 |
18 |
| Boehringer Ingelheim International GmbH | 4483 |
18 |
| F. Hoffmann-La Roche AG | 7815 |
17 |
| Janssen Pharmaceutica N.V. | 3161 |
16 |
| Curis, Inc. | 131 |
15 |
| Allergan, Inc. | 2159 |
14 |
| Shionogi & Co., Ltd. | 885 |
13 |
| Genentech, Inc. | 4115 |
12 |
| The Regents of the University of California | 20802 |
11 |
| The Trustees of Columbia University in the City of New York | 3644 |
10 |
| Gilead Sciences, Inc. | 2231 |
10 |
| Rigel Pharmaceuticals, Inc. | 505 |
10 |
| Glaxo Group Limited | 4375 |
9 |
| Agios Pharmaceuticals, Inc | 227 |
9 |
| Merck Patent GmbH | 5735 |
8 |
| Hoffmann-La Roche Inc. | 3815 |
7 |
| Other owners | 841 |